期刊
AIDS
卷 26, 期 10, 页码 1293-1302出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/QAD.0b013e32835474d2
关键词
clinical trials; HIV-1; immunogen design; vaccine
资金
- Vaccine Research Center, NIAID, National Institutes of Health
There is renewed optimism that the goal of developing a highly effective AIDS vaccine is attainable. The HIV-1 vaccine field has seen its first trial of a vaccine candidate that prevents infection. Although modest in efficacy, this finding, along with the recent discovery that the human immune system can produce broadly neutralizing antibodies capable of inhibiting greater than 90% of circulating viruses, provides a guide for the rational design of vaccines and protection by passive immunization. Together, these findings will help shape the next generation of HIV vaccines. (C) 2012 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据